LOGIN  |  REGISTER
Viking Therapeutics

TruBridge Announces Date for Second Quarter 2024 Conference Call

July 25, 2024 | Last Trade: US$13.00 0.03 0.23

MOBILE, Ala. / Jul 25, 2024 / Business Wire / TruBridge (NASDAQ: TBRG), a healthcare solutions company, today announced that it will release its financial results for the second quarter ended June 30, 2024, on Thursday, August 8, 2024, after the market closes. The Company will host a conference call at 4:30 p.m. Eastern Time that same day. To access this interactive teleconference, dial (800) 715-9871 and request connection to the TruBridge earnings conference call.

A live broadcast of TruBridge’s conference call will also be available online at the Company’s website, www.trubridge.com. The 30-day online replay will be available approximately an hour following the conclusion of the live broadcast.

About TruBridge

We are a trusted partner to more than 1,500 healthcare organizations with a broad range of technology-first solutions that address the unique needs and challenges of diverse communities, promoting equitable access to quality care and fostering positive outcomes. TruBridge has over four decades of experience in connecting providers, patients and communities with innovative data-driven solutions that create real value by supporting both the financial and clinical side of healthcare delivery. Our industry leading HFMA Peer Reviewed® suite of revenue cycle management (RCM) offerings combine unparalleled visibility and transparency to enhance productivity and support the financial health of healthcare organizations across all care settings. We support efficient patient care with electronic health record (EHR) product offerings that successfully integrate data between care settings. Above all, we believe in the power of community and encourage collaboration, connection, and empowerment with our customers. We clear the way for care. For more information, please visit www.trubridge.com.

Assertio

Stock Quote

Featured Stock

Astria Therapeutics

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...

CLICK TO LEARN MORE

Featured Stock

Chimerix

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB